Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -3.37 is 88% below its 5-year average of -1.79, near the low end of its 5-year range (-3.72–2.46).
1.32% above its 12-month average of -3.42.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.81.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 23 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T12:45:55.992Z. Historical observations retain their original dates. Historical series through 2023-08-10.
EARNINGS PER SHARE (EPS)
-3.37
EARNINGS PER SHARE (EPS) AVG TTM
-3.42
EARNINGS PER SHARE (EPS) AVG 3Y
-2.02
EARNINGS PER SHARE (EPS) AVG 5Y
-1.79
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+1.32%
CURRENT VS 3Y AVG
-67.25%
CURRENT VS 5Y AVG
-88.44%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Cullinan Therapeutics, Inc.
Market Cap
$985.79M
Earnings Per Share (EPS)
-3.37
TTM Avg
-3.42
3Y Avg
-2.02
5Y Avg
-1.79
Market Cap
$989.05M
Earnings Per Share (EPS)
-1.05
TTM Avg
-1.23
3Y Avg
-0.94
5Y Avg
-0.94
Market Cap
$943.26M
Earnings Per Share (EPS)
-1.76
TTM Avg
-1.29
3Y Avg
-1.36
5Y Avg
-1.36
Market Cap
$1.03B
Earnings Per Share (EPS)
-0.09
TTM Avg
-3.41
3Y Avg
-0.94
5Y Avg
-0.03
Market Cap
$1.04B
Earnings Per Share (EPS)
-1.84
TTM Avg
-0.83
3Y Avg
-0.99
5Y Avg
-2.01
Market Cap
$922.50M
Earnings Per Share (EPS)
0.78
TTM Avg
-0.28
3Y Avg
-0.36
5Y Avg
-0.51
Market Cap
$921.45M
Earnings Per Share (EPS)
0.72
TTM Avg
0.64
3Y Avg
0.54
5Y Avg
0.47
Market Cap
$1.05B
Earnings Per Share (EPS)
-0.99
TTM Avg
-3.50
3Y Avg
-23.24
5Y Avg
-16.84
Market Cap
$915.95M
Earnings Per Share (EPS)
0.77
TTM Avg
-0.09
3Y Avg
-1.31
5Y Avg
-0.73
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | $985.79M | -3.37 | -3.42 | -2.02 | -1.79 |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | -1.05 | -1.23 | -0.94 | -0.94 |
| CeriBell, Inc. (CBLL)vs › | $943.26M | -1.76 | -1.29 | -1.36 | -1.36 |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | -0.09 | -3.41 | -0.94 | -0.03 |
| Immatics N.V. (IMTX)vs › | $1.04B | -1.84 | -0.83 | -0.99 | -2.01 |
| Arbutus Biopharma Corp (ABUS)vs › | $922.50M | 0.78 | -0.28 | -0.36 | -0.51 |
| HealthStream, Inc. (HSTM)vs › | $921.45M | 0.72 | 0.64 | 0.54 | 0.47 |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | -0.99 | -3.50 | -23.24 | -16.84 |
| Bioventus Inc. (BVS)vs › | $915.95M | 0.77 | -0.09 | -1.31 | -0.73 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | -0.64 | -0.60 | -0.67 | -0.65 |
Trailing EPS (TTM)
$-3.37
Forward EPS (Est.)
$-3.17
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -3.72 |
| 2024-12-31 | -3.11 |
| 2023-12-31 | -3.69 |
| 2022-12-31 | 2.46 |
| 2021-12-31 | -1.48 |
| 2020-12-31 | -1.19 |
| 2019-12-31 | -19.70 |
| 2018-12-31 | -17.74 |
